logo

For the Inventor, By the Inventor

Saitama, Japan

Makoto Kajitani

This inventor holds 22 USPTO granted patents, plus 2 CIPO patents. Top assignees: Taiho Pharmaceutical Company Limited, University of Florida Research Foundation Inc.. Active years: 1981-1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Makoto Kajitani. Retrieved from https://idiyas.com/inventor/makoto-kajitani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22

% Patents Active = 100.0


Average Co-Inventor Count = 5.8

ph-index = 6

Forward Citations = 114(Granted Patents)


Location History:

  • Tokushima, JP (1981 - 1987)
  • Irumagun, JP (1993 - 1994)
  • Saitama, JP (1991 - 1998)
  • Hidaka, JP (1993 - 1999)

Company Filing History:

goldMedal22 out of 320 
 
Taiho Pharmaceutical Company Limited
 patents
silverMedal1 out of 3,050 
 
University of Florida Research Foundation Inc.
 patents
where one patent can have more than one assignee

Years Active: 1981-1999

Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents
1. 5869464 - 2'-Deoxy-5-fluorouridine derivatives, a process for their preparation, (1999-02-09),
2. 5734059 - Production intermediate and process for producing pyridine derivative (1998-03-31),
3. 5447944 - Carbamoyl-2-pyrrolidinone compounds (1995-09-05),
4. 5401739 - Benzothiadiazine derivatives (1995-03-28),
5. 5318970 - Isoxazole compounds, pharmaceutically acceptable salts thereof and (1994-06-07),
6. 5310926 - Process for producing isoxazole derivatives (1994-05-10),
7. 5229402 - Carbamoyl-2-pyrrolidinone compounds (1993-07-20),
8. 5214039 - Bicyclolactam derivative for improving cerebral function (1993-05-25),
9. 5206261 - Oxindole derivative (1993-04-27),
10. 5185344 - Pharmaceutically useful bicyclolactam derivative (1993-02-09),
11. 5182284 - Piperazine compounds, processes for preparation thereof and medical uses (1993-01-26),
12. 5142091 - .alpha., .beta.-unsaturated ketones and ketoxime derivatives (1992-08-25),
13. 5068235 - Diazabicycloalkane derivative (1991-11-26),
14. 4668514 - Penicillin derivatives (1987-05-26),
15. 4666911 - Allophanoylpiperazine compound and analgesic composition containing same (1987-05-19),

Title: Innovations and Contributions of Makoto Kajitani

Introduction: Makoto Kajitani, based in Saitama, Japan, has significantly contributed to the field of pharmaceuticals through his innovative inventions. With a remarkable portfolio of 22 patents, his work has had a substantial impact on drug development and production processes.

Latest Patents: Among his latest patents are critical developments in medicinal chemistry, including "2'-Deoxy-5-fluorouridine derivatives, a process for their preparation" and "Production intermediate and process for producing pyridine derivative." These patents showcase his expertise in creating efficient synthesis processes for complex compounds.

Career Highlights: Throughout his career, Makoto has worked with prestigious organizations, including Taiho Pharmaceutical Company Limited and the University of Florida. His contributions have helped advance therapeutic options in various medical areas, illustrating his dedication to innovation in the pharmaceutical industry.

Collaborations: Makoto has collaborated with notable individuals such as Mitsugi Yasumoto and Takaji Honna. These partnerships have facilitated the development of groundbreaking technologies, enhancing the impact of his inventions in real-world applications.

Conclusion: Makoto Kajitani's impressive patent portfolio and collaborations underline his role as an influential inventor in the pharmaceutical sector. His continuous pursuit of innovation not only supports the advancement of medical science but also ensures improved healthcare solutions for the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…